23
Participants
Start Date
October 31, 2006
Primary Completion Date
November 30, 2008
Study Completion Date
November 30, 2008
AT-101
AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
Rituximab
Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
Oncology and Hematology Associates of SW Virginia, Inc., Salem
St. Mary's Medical Center, Huntington
Duke University Medical Center, Durham
Florida Cancer Institute, New Port Richey
Florida Cancer Institute, Hudson
University of Alabama at Birmingham, Birmingham
The Jones Clinic, Germantown
University of Michigan Cancer Center, Ann Arbor
Hematology Oncology Physicians of Texas, Richardson
Hematology/Oncology Associates, Albuquerque
Cancer Care Northwest, Spokane
Hematology Oncology Associates, Phoenix
Rocky Mountain Cancer Center-Aurora, Aurora
Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights
Central Indiana Cancer Centers, Fishers
Minnesota Oncology Hematology, P.A., Minneapolis
Missouri Cancer Associates, Columbia
Comprehensive Cancer Centers of Nevada, Henderson
New York Oncology Hematology, P.C., Albany
Northwest Cancer Specialists, Portland
Texas Oncology, P.A., Bedford
Texas Cancer Center at Medical City, Dallas
Texas Oncology, P.A., Fort Worth
Allison Cancer Center, Midland
HOAST - New Braunfels, New Braunfels
West Texas Cancer Center, Odessa
Tyler Cancer Center, Tyler
Virginia Oncology Associates, Chesapeake
Lead Sponsor
Ascenta Therapeutics
INDUSTRY